Exploring the Patient Perspective in Pulmonary Hypertension

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2024 Aug 29

PMID 39209479

Authors

H James Ford

Colleen Brunetti

Pisana Ferrari

Gergely Meszaros

Victor M Moles

Hall Skaara

Adam Torbicki

J Simon R Gibbs

Affiliations

Soon will be listed here.

Abstract

The global impacts of pulmonary hypertension (PH) were formally recognised in 1973 at the 1st World Health Organization meeting dedicated to primary pulmonary hypertension, held in Geneva. Investigations into disease pathogenesis and classification led to the development of numerous therapies over the ensuing decades. While the impacts of the disease have been lessened due to treatments, the symptoms and adverse effects of PH and its therapies on patients' wellbeing and mental health remain significant. As such, there is a critical need to enhance understanding of the challenges patients face on a global scale with respect to care access, multidimensional patient support and advocacy. In addition, thoughtful analysis of the potential benefits and utilisation of mechanisms for the incorporation of patient-reported outcomes into diagnosis and treatment plans is needed. A summary of these areas is included here. We present a report of global surveys of patient and provider experiences and challenges regarding care access and discuss possible solutions. Also addressed is the current state of PH patient associations around the world. Potential ways to enhance patient associations and enable them to provide the utmost support are discussed. A summary of relevant patient-reported outcome measures to assess health-related quality of life in PH is presented, with suggestions regarding incorporation of these tools in patient care and research. Finally, information on how current global threats such as pandemics, climate change and armed conflict may impact PH patients is offered, along with insights as to how they may be mitigated with advanced contingency planning.

References

Bernardo R, de Jesus Perez V . Health Care Disparities in Pulmonary Arterial Hypertension. Clin Chest Med. 2023; 44(3):543-554. PMC: 10715710. DOI: 10.1016/j.ccm.2023.03.010. View

Mocumbi A, Mastala A, Guambe P, Dzudie A . Pulmonary vascular disease in Africa: Lessons from registries. Glob Cardiol Sci Pract. 2020; 2020(1):e202002. PMC: 7590930. DOI: 10.21542/gcsp.2020.2. View

Chen J, Ou L, Hollis S . A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res. 2013; 13:211. PMC: 3700832. DOI: 10.1186/1472-6963-13-211. View

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022; 61(1). DOI: 10.1183/13993003.00879-2022. View

Dzudie A, Dzekem B, Ojji D, Kengne A, Mocumbi A, Sliwa K . Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa. Cardiovasc Diagn Ther. 2020; 10(2):316-324. PMC: 7225434. DOI: 10.21037/cdt.2019.07.06. View

Grinnan D, Kang L, DeWilde C, Badesch D, Benza R, Bull T . Prediction of patient outcomes through social determinants of health: The Pulmonary Hypertension Association Registry (PHAR) evaluation. Pulm Circ. 2022; 12(3):e12120. PMC: 9330350. DOI: 10.1002/pul2.12120. View

DuBrock H, Reddy Y, Durst L, Schroeder D, Park G, Cajigas H . The feasibility and value of assessing patient-reported outcomes in pulmonary arterial hypertension. Pulm Circ. 2022; 12(4):e12143. PMC: 9575699. DOI: 10.1002/pul2.12143. View

Crossnohere N, Brundage M, Calvert M, King M, Reeve B, Thorner E . International guidance on the selection of patient-reported outcome measures in clinical trials: a review. Qual Life Res. 2020; 30(1):21-40. DOI: 10.1007/s11136-020-02625-z. View

McKenna S, Doughty N, Meads D, Doward L, Pepke-Zaba J . The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006; 15(1):103-15. DOI: 10.1007/s11136-005-3513-4. View

10.

Watts N, Amann M, Arnell N, Ayeb-Karlsson S, Beagley J, Belesova K . The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises. Lancet. 2020; 397(10269):129-170. PMC: 7616803. DOI: 10.1016/S0140-6736(20)32290-X. View

11.

Harikrishnan S, Sanjay G, Ashishkumar M, Menon J, Rajesh G, Kumar R . Pulmonary hypertension registry of Kerala, India (PRO-KERALA) - Clinical characteristics and practice patterns. Int J Cardiol. 2018; 265:212-217. DOI: 10.1016/j.ijcard.2018.02.036. View

12.

Feldman-Stewart D, Brundage M . A conceptual framework for patient-provider communication: a tool in the PRO research tool box. Qual Life Res. 2008; 18(1):109-14. DOI: 10.1007/s11136-008-9417-3. View

13.

Boyce M, Browne J . Does providing feedback on patient-reported outcomes to healthcare professionals result in better outcomes for patients? A systematic review. Qual Life Res. 2013; 22(9):2265-78. DOI: 10.1007/s11136-013-0390-0. View

14.

Lin P, Jiang F, Li X, Zhao Y, Shi Y, Liang Z . International trends in pulmonary hypertension mortality between 2001 and 2019: Retrospective analysis of the WHO mortality database. Heliyon. 2024; 10(4):e26139. PMC: 10879023. DOI: 10.1016/j.heliyon.2024.e26139. View

15.

Loomba S, de Figueiredo A, Piatek S, de Graaf K, Larson H . Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nat Hum Behav. 2021; 5(3):337-348. DOI: 10.1038/s41562-021-01056-1. View

16.

Coursen J, Simpson C, Mukherjee M, Vaught A, Kutty S, Al-Talib T . Pregnancy Considerations in the Multidisciplinary Care of Patients with Pulmonary Arterial Hypertension. J Cardiovasc Dev Dis. 2022; 9(8). PMC: 9409449. DOI: 10.3390/jcdd9080260. View

17.

Sahloul M, Monla-Hassan J, Sankari A, Kherallah M, Atassi B, Badr S . War is the Enemy of Health. Pulmonary, Critical Care, and Sleep Medicine in War-Torn Syria. Ann Am Thorac Soc. 2016; 13(2):147-55. DOI: 10.1513/AnnalsATS.201510-661PS. View

18.

Brundage M, Bass B, Jolie R, Foley K . A knowledge translation challenge: clinical use of quality of life data from cancer clinical trials. Qual Life Res. 2011; 20(7):979-85. DOI: 10.1007/s11136-011-9848-0. View

19.

Perone S, Martinez E, Du Mortier S, Rossi R, Pahud M, Urbaniak V . Non-communicable diseases in humanitarian settings: ten essential questions. Confl Health. 2017; 11:17. PMC: 5602789. DOI: 10.1186/s13031-017-0119-8. View

20.

Bunclark K, Doughty N, Michael A, Abraham N, Ali S, Cannon J . A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension. Pulm Circ. 2021; 11(2):2045894021995055. PMC: 8149778. DOI: 10.1177/2045894021995055. View